Movement Alert｜10x Genomics, Inc. Intraday Decline 9.66%, analyst target cuts continue to weigh despite raised full-year revenue outlook

Market Focus11-12 22:55

On November 12, 10x Genomics, Inc. fell 9.66% in Regular Trading, trading at $57.84 per share, with turnover of $36.57 million.

The move came as investors continued to weigh stronger-than-expected third-quarter results and a raised full-year revenue outlook against post-earnings analyst target cuts that kept valuation pressure elevated.

In its latest quarterly report, 10x Genomics, Inc. posted a loss of $0.15 per share, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million exceeded consensus near $148 million. The company raised full-year revenue guidance to $625 million-$635 million, above the roughly $620.8 million market expectation. Even so, analysts remained cautious, with recently updated targets including $61, $70, and $65, underscoring an ongoing debate between improving operating trends and a more restrained valuation framework.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment